At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
879.06MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.43xvs all stocks
52-Week Change
37.68%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
879.06MUSDvs all stocks (USD)
Enterprise Value
671.29MUSDvs all stocks (USD)
Forward P/E
-9.86xvs Biotechnology peers
Price to Book (MRQ)
3.93xvs Biotechnology peers
Enterprise to EBITDA
-11.81xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.66%vs Biotechnology peers
Return on Equity (TTM)
-35.43%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-56.85MUSDvs all stocks (USD)
Net Income (TTM)
-54.13MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-44.53MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-27.40MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-42.97MUSDvs all stocks (USD)
Pre-tax Income
-15.28MUSDFY2025 · Dec 31, 2025Net Income
-15.28MUSDFY2025 · Dec 31, 2025EBIT
-42.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-70.01MUSDFY2025 · Dec 31, 2025Research & Development
33.72MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.50MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-9.97MUSDFY2025 · Dec 31, 2025Free Cash Flow
-10.14MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.58MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
105.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
38.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-91.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-70.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-174.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-91.75MUSDFY2025 · Dec 31, 2025Sale of Investments
84.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
84.12MSharesUpdated Oct 27, 2026Float Shares
72.79MSharesUpdated Oct 27, 2026Shares Short
17.80MSharesUpdated Oct 27, 2026Short Ratio
15.44daysvs all stocks
Short % of Shares Outstanding
24.05%vs all stocks
% Held by Insiders
3.51%vs all stocks
% Held by Institutions
85.82%vs all stocks
Total Cash (MRQ)
215.23MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.56USDUpdated Oct 27, 2026Total Debt (MRQ)
728.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0032xvs Biotechnology peers
Current Ratio (MRQ)
16.16xvs Biotechnology peers
Book Value per Share (MRQ)
2.68USDUpdated Oct 27, 2026Total Assets
71.12MUSDvs all stocks (USD)
Total Current Assets
58.21MUSDFY2025 · Dec 31, 2025Total Liabilities
9.91MUSDFY2025 · Dec 31, 2025Total Non-current Assets
12.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
534.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
52.17MUSDFY2025 · Dec 31, 2025Accounts Receivable
37.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.49MUSDFY2025 · Dec 31, 2025Short-term Debt
403.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
238.00KUSDFY2025 · Dec 31, 2025Long-term Debt
534.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-412.29MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
61.20MUSDvs all stocks (USD)
52-Week Low
6.39USDUpdated Oct 27, 202652-Week High
26.95USDUpdated Oct 27, 202652-Week Change
37.68%vs all stocks
Beta
1.43xvs all stocks
50-Day MA
12.39USDUpdated Oct 27, 2026200-Day MA
14.35USDUpdated Oct 27, 2026Avg 10-Day Volume
1.02MSharesUpdated Oct 27, 2026Avg 30-Day Volume
1.22MSharesUpdated Oct 27, 2026Diluted EPS (TTM)
-0.6200USDUpdated Oct 27, 2026Other Income / Expense
25.18MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 245
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking